Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC).
Jennifer W. Carlisle(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), Charles E. Hill(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Nhu Thi Nho(Emory University), Chaejin Kim(Emory University), Suresh S. Ramalingam(Emory University), Shiyong Li(Emory University)
Cited by 13
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899